Dose requirements for healthy people (without any medical conditions associated with increased risk of invasive meningococcal disease)
6 weeks to 5 months
Menveoa Nimenrix
3 doses (8 weeks between 1st and 2nd doses; 3rd dose at 12 months of age)
6–11 months
Menveo Nimenrix
2 doses (2nd dose at 12 months of age or 8 weeks after 1st dose, whichever is later)
12–23 months
MenQuadfi
1 dose
Menveo
2 doses (8 weeks between doses)
Nimenrix
1 dose
a. For optimal protection against serogroup A, an extra primary dose (ie a 3+1 schedule) of Menveo should be considered for infants who commence vaccination aged <6 months due to planned travel to areas where meningococcal A disease is common.
